News for October and November

As we see out September, it’s good to look at what is imminent. During October/November I expect the signing of the US agreement and the FDA approval. Please add to these:

- AZD0466 to commence clinical trials in FY19 (from p.18 SPL annual report). Patent application subsequently published and announced 31 August 2018
- Dep irinotecan to commence clinical trials and final preclinical work underway in preparation (p.15 annual report)
- FDA approval 6-8 months from submission date on 30 April 2018.
- Announcement of US vivagel distributor, described as in “advanced negotiations” on p3 of the annual report.
- further DEP portfolio milestones in the year ahead (again from page 2 of the annual report).